Log in

Relevant bibliographies by topics / CYP2CP; VKORC1; Thromboembolism

Contents

Journal articles

Academic literature on the topic 'CYP2CP; VKORC1; Thromboembolism'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CYP2CP; VKORC1; Thromboembolism.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CYP2CP; VKORC1; Thromboembolism"

1

RanakishorPelluri*, Panguluri Haripriya Mantri Satyavathi V. Lakshmi Prasanna Shaik SeshmaIfthulla P.SrinivasaBabu. "WARFARIN DOSAGE ADJUSTMENT IN PATIENTS WITH GENETIC VARIABILITY." INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH 07, no. 09 (2017): 488–91. https://doi.org/10.5281/zenodo.1036431.

Full text

Abstract:

Warfarin is a potent drug that when used judiciously and monitored closely, leads to substantial reductions in morbidity and mortality from thromboembolic events. However, even with careful monitoring, initiation of warfarin dosing is associated with highly variable responses between individuals and challenges achieving and maintaining levels within the narrow therapeutic range that can lead to adverse drug events. Genetic factors most correlated with warfarin dose requirements are variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR).

APA, Harvard, Vancouver, ISO, and other styles

2

Anekella, Bharathi, Jainlei Wu, Catherine Huang, et al. "Characterization and Development of Genomic DNA Quality Controls for Thrombophilia and Warfarin Sensitivity Testing." Blood 112, no. 11 (2008): 4679. http://dx.doi.org/10.1182/blood.v112.11.4679.4679.

Full text

Abstract:

Abstract Background: Genetic tests for diagnosis of clotting disorders and monitoring their treatment are based on identification of single nucleotide polymorphisms (SNPs) that are related respectively to clotting and to drug metabolism crucial to the effectiveness of therapy. Thrombophilia, an inherited condition which predisposes to thromboembolism, is due in part to genetic factors, such as the presence of SNPs in the genes encoding clotting factors. Hyperhomocysteinemia, which poses an extremely elevated risk of thromboembolism to the patient, can be caused by certain mutations to the MTHF

APA, Harvard, Vancouver, ISO, and other styles

3

Gong, Inna Y., Rommel G. Tirona, Ute I. Schwarz, et al. "Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy." Blood 118, no. 11 (2011): 3163–71. http://dx.doi.org/10.1182/blood-2011-03-345173.

Full text

Abstract:

Abstract Single-nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene, VKORC1) have an important influence on warfarin therapy, particularly during initiation; however, there is a lack of consensus regarding the optimal pharmacogenetics-based initiation strategy. We conducted a prospective cohort study in which patients requiring warfarin therapy for atrial fibrillation or venous thromboembolism were initiated with a novel pharmacogenetics-initiation protocol (WRAPID, Warfarin Regimen using

APA, Harvard, Vancouver, ISO, and other styles

4

Tzveova, R., R. Saraeva, A. Dimitrova-Karamfilova, et al. "Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants." Acta Medica Bulgarica 52, no. 2 (2025): 12–23. https://doi.org/10.2478/amb-2025-0039.

Full text

Abstract:

Abstract Introduction Acenocoumarol, a 4-hydroxycoumarin derivative, is widely prescribed for the primary and secondary prevention of thromboembolic disorders. Maintenance dosing of acenocoumarol is significantly influenced by polymorphic variants in the CYP2C9 and VKORC1 genes. Other critical factors affecting dosing include patient age, diet, body height and weight, and potential drug interactions, particularly with concurrent use of medications such as amiodarone and statins. Objectives The primary goal of this investigation is to develop a pharmacogenetic dosing algorithm for acenocoumarol

APA, Harvard, Vancouver, ISO, and other styles

5

Tanaka, Tomotaka, Masafumi Ihara, Kazuki Fukuma, et al. "Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients." Genes 12, no. 10 (2021): 1537. http://dx.doi.org/10.3390/genes12101537.

Full text

Abstract:

The genotypes of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) can influence therapeutic warfarin doses. Conversely, nongenetic factors, especially renal function, are associated with warfarin maintenance doses; however, the optimal algorithm for considering genes and renal dysfunction has not been established. This single-center prospective cohort study aimed to evaluate the factors affecting warfarin maintenance doses and develop pharmacogenetics-guided algorithms, including the factors of renal impairment and others. To commence, 176 outpatients who were pr

APA, Harvard, Vancouver, ISO, and other styles

6

YAY, Kerem, Alper İbrahim TOSYA, and Zafer Cengiz ER. "DO VKORC1 AND CYP2C9 MUTATIONS LEAD TO WARFARIN RESISTANCE?" Euroasia Journal of Mathematics, Engineering, Natural & Medical Sciences 8, no. 18 (2021): 100–104. http://dx.doi.org/10.38065/euroasiaorg.768.

Full text

Abstract:

The objective of this study was to determine the influence of VKORC1 and CYP2C9 polymorphisms on warfarin resistant patients. Warfarin resistance is described as the inability to prolong the prothrombin time or raise the INR up to the 2 therapeutic range when the drug is given at typically doses. Polymorphisms may play a role as some VKORC1 and CYP2C9 variant alleles are known to be associated with these circumstances. 28 patients who were taking warfarin more than 15 mg/day and had INR values below 2.1 and had thromboembolic events while using warfarin were enrolled in this study. Heterozygot

APA, Harvard, Vancouver, ISO, and other styles

7

Jiménez-Varo, Enrique, Marisa Cañadas-Garre, María José Gutiérrez-Pimentel, Cristina Isabel Henriques, Ana Margarida Pinheiro, and Miguel Ángel Calleja-Hernández. "Pharmacogenetics role in the safety of acenocoumarol therapy." Thrombosis and Haemostasis 112, no. 09 (2014): 522–36. http://dx.doi.org/10.1160/th13-11-0941.

Full text

Abstract:

SummaryVitamin K antagonists (VKAs) remain as the most prescribed drug for treatment and prevention of thrombotic disorders in many countries, despite the recent approval of the new oral anticoagulants (NOACs). Although effectiveness and safety of VKAs are tightly associated to maintaining the patient within the international normalised ratio (INR) therapeutic range (TWR), they have been likened to NOACs when patients are in good INR control (≥66% of TWR). Therefore, assessing the safety of patients should be a priority in the selection of the anticoagulation therapy. The aim of this study was

APA, Harvard, Vancouver, ISO, and other styles

8

Georgieva, K. S., and S. I. Pavlova. "Prevalence of CYP2C9 and VKORC1 polymorphism carriage in patients of the Chuvash population receiving warfarin." Glavvrač (Chief Medical Officer), no. 4 (March 22, 2025): 37–38. https://doi.org/10.33920/med-03-2504-06.

Full text

Abstract:

Warfarin is an anticoagulant with proven efficacy in preventing thromboembolic complications in patients with mechanical heart valves. Genetic characteristics of the patient, such as carriage of polymorphisms responsible for its pharmacokinetics (CYP2C9) and pharmacodynamics (VKORC1) are significant when selecting doses of this drug.

APA, Harvard, Vancouver, ISO, and other styles

9

Николаев, Е. Е., А. В. Богданов, С. И. Павлова, and С. М. Богданова. "Clinical Case of Warfarin Resistance in a Patient with Prosthetic Heart Valves and the CYP2C9*1*1-VKORC1GG Genotype." Кардиология в Беларуси, no. 3 (July 13, 2020): 432–38. http://dx.doi.org/10.34883/pi.2020.12.3.011.

Full text

Abstract:

Использование непрямых антикоагулянтов, в частности варфарина, является обязательным для профилактики тромбозов у пациентов с протезированными клапанами сердца. В статье представлен клинический случай резистентности к варфарину у пациента с имплантированными митральным и аортальным клапанами. В период его стационарного лечения наблюдались трудности в подборе дозы варфарина для достижения целевого международного нормализованного отношения (МНО), отмечались тромбоэмболические и геморрагические осложнения. В публикации рассмотрены генетические и другие факторы, с которыми могла быть связана устой

APA, Harvard, Vancouver, ISO, and other styles

10

Gage, B. F., C. S. Eby, J. A. Johnson, et al. "Use of Pharmacogenetics and Clinical Factors To Predict the Maintenance Dose of Warfarin." Blood 106, no. 11 (2005): 550. http://dx.doi.org/10.1182/blood.v106.11.550.550.

Full text

Abstract:

Abstract Background Initiation of warfarin therapy using trial-and-error dosing can cause bleeding. Clinical factors explain only 20%–30% of the variability in the therapeutic dose of warfarin. Single nucleotide polymorphisms (SNPs) in the cytochrome P450 2C9 (CYP2C9) gene correlate with the clearance of S-warfarin and SNPs in the vitamin K epoxide reductase (VKORC1) gene predict warfarin sensitivity. We test the hypothesis that the combination of clinical and pharmacogenetic information can predict the therapeutic warfarin dose. Methods We collected DNA, demographic variables, laboratory valu

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!